Towards reducing resistance and haematological toxicity of linezolid

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/284347

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Multi-drug resistance in bacteria is increasing at an alarming rate. We have diminishing therapeutic options, and there are few antibiotics in the drug development pipeline that offer much hope. It is therefore important that we look towards ways of further optimising the use of antibiotics that we currently have available. An important last line of defense drug, linezolid, has been available in Australia for less than 2 years and already resistance is occuring. In addition, with broader use of this drug outside clinical trials, there has been an increasing concern over its toxicity to important blood cells. We seek to better understand the determinants of linezolid resistance and toxicity, so that novel dosing strategies may be developed to optimise its use (reduce toxicity and enhance efficacy) thereby extending the usefulness of this last line of defense antibiotic.

Funded Activity Details

Start Date: 01-01-2004

End Date: 01-01-2005

Funding Scheme: NHMRC Project Grants

Funding Amount: $135,825.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical biochemistry - inorganic elements and compounds

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Adverse drug reactions and toxicity | Antimicrobial pharmacodynamics | Antimicrobial pharmacokinetics | Antimicrobial resistance | Antimicrobial toxicity and toxicodynamics | Final therapeutic option | Multidrug-resistant bacterial infections | Optimising antimicrobial dosage | Severely ill patients

Related Links